This Year's Highlights

• RhinoCyteTM completed a positive pre-IND meeting with the FDA in April 2007 which resulted in a roadmap for successful IND submission. Per FDA advice, RhinoCyteTM expects to complete preclinical phase by 3Q 2008. IND submission is planned for 1Q 2009.
• On July 11, 2007, RhinoCyteTM submitted an Orphan Drug Designation Application to the FDA for the lead product which provides for treatment of sub-acute spinal cord injuries.
• Concurrent with lead product development, the Company is conducting additional proof of concept studies to determine the feasibility of this technology to treat Parkinson?s disease and other neurodegenerative diseases.

Anticipated Highlights

• The Company is seeking a $10-12M institutional round of financing to take the lead product through final IND submission, initiate a Phase I clinical trial in SCI, hire full-time management and pursue preclinical work on future indications.

Corporate Mission

RhinoCyteTM will be a leader in the advancement of cell based therapies by providing innovative autologous adult human cell solutions to treat a variety of neurodegenerative disorders.

The Company

RhinoCyteTM, Inc. is an early stage biotechnology company focused on commercializing autologous adult olfactory-derived stem cell therapies to treat spinal cord injury (SCI) and neurodegenerative disorders such as Parkinson?s disease, Multiple Sclerosis and Amyotrophic Lateral Sclerosis.

The foundation of RhinoCyte?s proprietary technology involves harvesting, isolating, engineering, expanding, cyropreserving and engrafting autologous adult cells, circumventing histocompatibility and immunosuppressive issues while avoiding ethical concerns. The feasibility of this technology to treat spinal cord injury and other neurodegenerative diseases has been demonstrated through basic and translational research.

RhinoCyteTM will offer the service for its cutting edge technology of isolating and processing the olfactory-derived neural progenitors. Once obtained and primed, the progenitors will be released to the clinical site for implantation into the patient. Should clinical management warrant multiple treatments, RhinoCyteTM will additionally offer cryo-banking of the progenitors.